MBRX | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 9%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-8.37%

1 Month

-49.51%

3 Months

-71.31%

6 Months

434.70%

1 Year

80.87%

2 Year

-79.43%

Key data

Stock price

$2.08

P/E Ratio

0.00

DAY RANGE

$2.05 - $2.24

EPS

-$2.41

52 WEEK RANGE

$0.25 - $7.98

52 WEEK CHANGE

$80.87

MARKET CAP

16.052 M

YIELD

N/A

SHARES OUTSTANDING

50.910 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-09-2025

BETA

3.70

PUBLIC FLOAT

AVERAGE 10 VOLUME

$115,015

AVERAGE 30 VOLUME

$258,035

Company detail

CEO: Walter V. Klemp
Region: US
Website: moleculin.com
Employees: 20
IPO year: 2016

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the. treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in clinical trials for brain tumors and pediatric brain tumors.

MBRX - Moleculin Biotech, Inc.